Select Language
Tau
Tau Overview
| English Name | Microtubule-associated protein tau | Approved Drugs | 1 |
| Drugs in Clinical Trials | 45 | Target Synonym | MAPT，MTBT1，Paired helical filament-tau，MAPTL，Microtubule Associated Protein Tau，G Protein Beta1/Gamma2 Subunit-Interacting Factor 1，Protein Phosphatase 1， Regulatory Subunit 103，Neurofibrillary Tangle Protein，PHF-Tau，TAU，Microtubule-Associated Protein Tau， Isoform 4，Microtubule-Associated Protein Tau，PPP1R103，FTDP-17，MTBT2，DDPAC，MSTD，PPND，tau Proteins，MGC138549，FLJ31424 |
| Highest Development Stage | Approved | ||
| English Name | Microtubule-associated protein tau |
| Target Synonym | MAPT，MTBT1，Paired helical filament-tau，MAPTL，Microtubule Associated Protein Tau，G Protein Beta1/Gamma2 Subunit-Interacting Factor 1，Protein Phosphatase 1， Regulatory Subunit 103，Neurofibrillary Tangle Protein，PHF-Tau，TAU，Microtubule-Associated Protein Tau， Isoform 4，Microtubule-Associated Protein Tau，PPP1R103，FTDP-17，MTBT2，DDPAC，MSTD，PPND，tau Proteins，MGC138549，FLJ31424 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 45 |
| Highest Development Stage | Approved |
Tau Product List
- Product Category
Protein (20)Cell (1)Antibody (2)
- Product Status
Launched (23)
- Species
Human (20)Cynomolgus (1)Mouse (2)
- Tag
His Tag (8)Tag Free (11)GFP Tag (1)- (2)His Tag & Avi Tag (1)
- Conjugate
Unconjugated (21)- (1)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT CHEK-ATP087 |  Human | HEK293 | HEK293/Human Tau-K18 (GFP) Stable Cell Line |  | ||
HOT TAU-H5113 | Human | E. coli | Human Tau-441 K18 (P301L) Pre-formed Fibrils Protein, Tag Free |  |  |  |
HOT TAU-H5115 | Human | E. coli | Human Tau-441 / 2N4R Pre-formed Fibrils Protein, Tag Free |  | | |
HOT TAU-H5117 | Human | E. coli | Human Tau-441 / 2N4R Protein, Tag Free, low endotoxin (MALS verified) |  | |  |
HOT TAU-H51H3 | Human | E. coli | Human Tau-441 / 2N4R Protein, His Tag, low endotoxin |  | | |
TAU-H5112 | Human | E. coli | Human Tau-381 / 1N3R Protein, Tag Free, low endotoxin (MALS verified) |  | | |
TAU-H5114 | Human | E. coli | Human Tau Protein, Tag Free, low endotoxin (MALS verified) |  | | |
TAU-H5116 | Human | E. coli | Human Tau-441 K18 Pre-formed Fibrils Protein, Tag Free |  | | |
TAU-H5118 | Human | E. coli | Human Tau-441 (K18, P301L) Protein, Tag Free, low endotoxin (MALS verified) |  | | |
TAU-H5119 | Human | E. coli | Human Tau-412 / 1N4R Protein, Tag Free, low Endotoxin (MALS verified) |  | | |
Total: 23
- 1
- 2
- 3
Tau Background
Tau is a microtubule-associated protein, which encodes by the MAPT gene that located on chromosome 17q21. Tau Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. Hyperphosphorylation of the tau protein (tau inclusions, pTau) can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease, frontotemporal dementia, and other tauopathies.
Tau Synonyms
DDPAC,FTDP-17,MAPT,MSTD,MTBT1,Tau,PHF-tau,TAU
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction; Down Syndrome; Frontotemporal Dementia; Parkinson Disease | Details |
| Florzolotau | F0-PBB3; PM-PBB3; [18F]APN-1607; [18F]MNI-958; APN-0000455; [18F]PM-PBB3; APN-1607; 18F-PM-PBB3; 18F-APN-1607 | Phase 3 Clinical | Aprinoia Therapeutics Ltd | Alzheimer Disease; Cognition Disorders; Cognitive Dysfunction; Diagnostic agents; Nerve Degeneration; Supranuclear Palsy, Progressive | Details |
| Etalanetug | E-2814 | Phase 3 Clinical | Eisai Co Ltd | Alzheimer Disease; Dementia | Details |
| Izaflortaucipir F-18 | PI-2620; 18F-PI-2620; [18F]PI-2620 | Phase 3 Clinical | Ac Immune Sa, Piramal | Alzheimer Disease; Brain Injuries, Traumatic; Cognitive Dysfunction; Frontotemporal Lobar Degeneration; Opioid-Related Disorders; Parkinson Disease; Supranuclear Palsy, Progressive | Details |
| [F-18]Flornaptitril | [F-18]FDDNP; F-18-FNT-PET | Phase 3 Clinical | University Of California At Los Angeles | Alzheimer Disease; Chronic Traumatic Encephalopathy | Details |
| XTR-006 | XTR-006 | Phase 3 Clinical | Beijing Xiantong International Technology Co Ltd | Alzheimer Disease; Tauopathies | Details |
| Zagotenemab | LY-3303560 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
| Posdinemab | JNJ-3657; JNJ-63733657 | Phase 2 Clinical | Johnson & Johnson Innovative Medicine | Alzheimer Disease; Cognitive Dysfunction; Dementia | Details |
| [18F]GTP-1 | [18F]GTP-1 | Phase 2 Clinical | Genentech Inc | Alzheimer Disease | Details |
| [18F]THK-5105 | [18F]THK-5105 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
| ISIS-814907 | BIIB-080; ISIS-814907; IONIS-MAPTRx; ISIS-BIIB4Rx; IONIS-BIIB4RX | Phase 2 Clinical | Biogen Inc, Ionis Pharmaceuticals Inc | Alzheimer Disease; Cognitive Dysfunction | Details |
| Tilavonemab | C2N-8E12; ABBV-8E12 | Phase 2 Clinical | C2n Diagnostics Llc | Alzheimer Disease; Supranuclear Palsy, Progressive | Details |
| Alzheimer's disease vaccine (Axon Neuroscience) | AADvac-1 | Phase 2 Clinical | Axon Biochemicals | Alzheimer Disease; Primary Progressive Nonfluent Aphasia; Supranuclear Palsy, Progressive | Details |
| Semorinemab | MTAU-9937A; MTAU9937A; RG-6100; RO7105705; RO-7105705 | Phase 2 Clinical | Ac Immune Sa | Alzheimer Disease | Details |
| APN-1701 | [18F]AM-PBB3; 18F-AM-PBB3; APN-1701 | Phase 2 Clinical | Aprinoia Therapeutics Ltd, National Institute Of Radiological Sciences | Alzheimer Disease; Nerve Degeneration | Details |
| VY-TAU-01 | VY-TAU01; VY-TAU-01; VY-7523 | Phase 2 Clinical | Voyager Therapeutics Inc | Alzheimer Disease | Details |
| Anti-tau antibody (Prothena) | BMS-986446; PRX-005 | Phase 2 Clinical | Prothena | Alzheimer Disease; Frontotemporal Dementia | Details |
| MK-2214 | MK-2214 | Phase 2 Clinical | Merck Sharp & Dohme LLC | Alzheimer Disease | Details |
| BEY-2153 | BEY-2153 | Phase 2 Clinical | Beyondbio Inc | Alzheimer Disease | Details |
| Bepranemab | UCB-0107; RG6416 | Phase 2 Clinical | Ucb | Alzheimer Disease; Supranuclear Palsy, Progressive | Details |
| [18F]THK-5117 | [18F]THK-5117 | Phase 2 Clinical | Tohoku University | Alzheimer Disease | Details |
| PNT-001 | PNT-001 | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Alzheimer Disease; Brain Injuries, Traumatic | Details |
| ReS19-T | ReS19-T | Phase 1 Clinical | Remynd | Alzheimer Disease | Details |
| Mecripyrine Hydrochloride | SCR-1693; Y-1A; Y-1 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd, NeuroDawn Pharmaceutical Co Ltd, Yantai Yene Pharma Co Ltd | Alzheimer Disease; Brain Neoplasms | Details |
| Lu-AF87908 | Lu-AF87908; Lu-AF-87908 | Phase 1 Clinical | H. Lundbeck A/S | Alzheimer Disease | Details |
| RDC-5 | RDC-5 | Phase 1 Clinical | Chronos Therapeutics Ltd | Amyotrophic Lateral Sclerosis | Details |
| MC-1 (Lilly) | MC-1 (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
| OLX-07010 | OLX07010 | Phase 1 Clinical | Oligomerix Inc | Alzheimer Disease; Dementia; Neurodegenerative Diseases; Supranuclear Palsy, Progressive | Details |
| Protollin | Phase 1 Clinical | The Brigham and Women's Hospital | Alzheimer Disease | Details | |
| NB-02 | NB-02; DA-9803 | Phase 1 Clinical | Dong-A ST Co Ltd | Alzheimer Disease; Lymphoma, Non-Hodgkin | Details |
| MAPT siRNA therapeutic (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neurodegenerative Diseases | Details | |
| 18F-JSS20-183A | 18F-JSS20-183A | Phase 1 Clinical | University Of Pennsylvania | Tauopathies | Details |
| ATC-102 | ATC-102; ATC102 | Phase 1 Clinical | Autotac Bio Inc | Alzheimer Disease | Details |
| AB-19 (AUTOTAC Bio) | AB-19 (AUTOTAC Bio) | Phase 1 Clinical | Autotac Bio Inc | Supranuclear Palsy, Progressive | Details |
| AB-12 po (AUTOTAC Bio) | AB-12 po | Phase 1 Clinical | Autotac Bio Inc | Alzheimer Disease | Details |
| DNL-628 | OTV:MAPT; DNL-628 | Phase 1 Clinical | Denali Therapeutics Inc | Alzheimer Disease | Details |
| [89Zr]Zr-DFO-BIIB080 | [89Zr]Zr-DFO; [89Zr]Zr-DFO-ISIS-814907 | Phase 1 Clinical | Biogen Inc | Details | |
| DA-7503 | DA-7503 | Phase 1 Clinical | Dong-A ST Co Ltd | Details | |
| LY-3954068 | LY3954068; LY-3954068 | Phase 1 Clinical | Eli Lilly And Company | Alzheimer Disease | Details |
| AS-603 | S-603; AS-603; AS-S603 | Phase 1 Clinical | Amyloid Solution Inc | Alzheimer Disease | Details |
| ADEL-Y01 | ADEL-Y01 | Phase 1 Clinical | ADEL Inc, Oscotec Inc | Alzheimer Disease; Tauopathies | Details |
| APNmAb-005 | APNmAb-005 | Phase 1 Clinical | Aprinoia Therapeutics Ltd | Alzheimer Disease; Nerve Degeneration; Tauopathies | Details |
| AV-1959R/AV-1980R | 1959R + 1980R; AV 1959R + AV 1980R | Phase 1 Clinical | Nuravax | Alzheimer Disease | Details |
| NIO-752 | NIO-752 | Phase 1 Clinical | Novartis Pharma Ag | Alzheimer Disease; Cognitive Dysfunction; Neurodegenerative Diseases; Supranuclear Palsy, Progressive | Details |
| 11C-PBB3 | 11C-PBB3 | Clinical | National Institute Of Radiological Sciences | Alzheimer Disease | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Flortaucipir F18 | 18F-AV-1451; T807; F-18-AV-1451; [18F]-T-807; [3H]AV 1451; [F-18]T807; [F18]AV1451; LY3191748 | Approved | Siemens Medical Solution | Tauvid | United States | Alzheimer Disease | Avid Radiopharmaceuticals Inc | 2020-05-28 | Alzheimer Disease; Aphasia, Primary Progressive; Brain Concussion; Brain Injuries; Brain Injuries, Traumatic; Chronic Traumatic Encephalopathy; Cognition Disorders; Cognitive Dysfunction; Corticobasal degeneration; Dementia; Depression; Diagnostic agents; Frontotemporal Dementia; Neurodegenerative Diseases; Parkinson Disease; Pick Disease of the Brain; Supranuclear Palsy, Progressive; Tauopathies | Details |
Product Reviews
P***g2021-08-24
5People LikeI have purchased multiple antigens from ACRO for discovery projects and I have found that the quality of antigens purchased from Acro is great!! Acro has become by go to vendor when I am looking for quality antigens. In addition, Acro also provides an impressive range of formats for each antigens, including different tags. Not to mention, their customer service team is fantastic. Overall, a great company to work with.
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland